Commercial ViabilityKOLs warned the commercial barriers may be high, with most feeling that SGLT2s would likely receive a Class 1 recommendation in the next guidelines.
Market DifferentiationIt's unclear how differentiated EDG-7500 will be in practice versus Afi.
Safety ConcernsSafety was more problematic, where beyond high rates of GI issues, one patient’s LVEF dropped below 50%, raising the prospect of a potential REMS with negative commercial read-throughs.